Table 5:
Published studies of sinonasal malignancy and radiation therapy
| Investigator | Patients | Surgery | Pathology | Proton Therapy Technique | Follow-up (mos) | LC % (years) | OS % (years) |
|---|---|---|---|---|---|---|---|
| National Cancer Center Japan, 2011 [35] | Treatment naïve, unresectable N=39 |
none | 28% SCC | No IMPT | 45.4 | 77% (1y) | 59% (3y) |
| National Cancer Center Japan, 2012 [37] | Treatment naïve, T4b only N=13 |
none | 23% SCC | No IMPT | 56.5 | 77% (5y) | 76% (5y) |
| National Cancer Center Japan, 2015 [42] | Treatment-naïve, 70% T3–T4 N=90 |
14% | 24%SCC | No IMPT | 57.5 | 77% (5y) | 75% (3y) |
| National Cancer Center Japan, 2017 [31] | Treatment naïve N=42 |
none | Olfactory neuro-blastoma | No IMPT | 69 | 39–80% (5y) | 76–100% (5y) |
| Massaachusetts Eye and Ear, 2008 [29] | Treatment naïve, Locally advanced N=102 |
69% | 32% SCC | No IMPT | 43 | 49% (5y) in biopsy only patients | 87% (5y) in biopsy only patients |
| Massachusetts General, 2009 [43] | Treatment naïve, locally advanced N=20 |
35% | 50% SCC | No IMPT | 27 | 86% (2y) | 53% (2y) |
| Massachusetts General, 2016 [32] | Treatment naïve, T3–T4 only N=54 |
69% | 100% SCC | No IMPT | 82 | 80% (2y) | 67% (2y) |
| University of Florida, 2016 [33] | Treatment naïve, 8% recurrent N=84 |
87% | 26% SCC | No IMPT | 28.8 | 83% (3y) | 68% (3y) |
| Massachusetts General, 2006 [36] | 92% advanced, 8% recurrent N=36 |
78% | 28% SCC | No IMPT | 52.4 | 89% (5y) | 81% (5y) |
| University of Tsukubu, 2012 [40] | Recurrent or T4 N=17 |
none | 64% SCC | No IMPT | 23 | 35% (2y) | 47% (2y) |
| CURRENT STUDY, 2019 | 79% treatment naïve, 21% reirradiation N=86 |
41%SCC | RT-naïve | 24.0 | 83% (2y) | 81% (2y) | |
| Re-RT | 23.4 | 77% (2y) | 66% (2y) |